Cassava Sciences Inc vs Western Union Co — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Western Union Co trades at $8.31 (market cap $2.51B). The key difference: Western Union Co is far larger — about 47.2× Cassava Sciences Inc's market cap, and Western Union Co pays a 11.69% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WU | |
|---|---|---|
Market Cap | $53.14M | $2.51B |
Sector | Health | Technology |
52-Week High | $4.64 | $10.28 |
52-Week Low | $1.09 | $7.04 |
Enterprise Value | -$33.43M | $2.21B |
Dividend Yield | — | 11.69% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Western Union (WU) trades at $8.275, up 5.01% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a 10.88% net income margin and 47.66% ROE, though recent Q1 2026 earnings missed expectations. Valuation ratios appear attractive with a P/E of 5.91 and P/S of 0.64. Recent developments include a partnership with Total Wireless for fee-free money transfers and progress on the Intermex acquisition, enhancing digital reach.
Outlook is mixed: low valuations and dividend yield near 5.8% offer value, but declining revenue from $4.5B in 2022 to $4.0B projected for 2026 poses growth concerns. Risks include high debt levels and competitive pressures. Analysts are cautious with a consensus hold rating and $7.50 price target below the current price, indicating limited upside potential amid execution challenges.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →